Literature DB >> 22983576

Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure.

Thomas Prébet1, Sylvain Thepot, Steven D Gore, François Dreyfus, Pierre Fenaux, Norbert Vey.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22983576      PMCID： PMC3561445          DOI： 10.3324/haematol.2012.071050

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

1.  Report of an international working group to standardize response criteria for myelodysplastic syndromes.

Authors:  B D Cheson; J M Bennett; H Kantarjian; A Pinto; C A Schiffer; S D Nimer; B Löwenberg; M Beran; T M de Witte; R M Stone; M Mittelman; G F Sanz; P W Wijermans; S Gore; P L Greenberg
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

Review 2.  How I treat patients with myelodysplastic syndromes.

Authors:  Richard M Stone
Journal:  Blood       Date:  2009-04-21       Impact factor: 22.113

3.  Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

Authors:  Alan List; Gordon Dewald; John Bennett; Aristotle Giagounidis; Azra Raza; Eric Feldman; Bayard Powell; Peter Greenberg; Deborah Thomas; Richard Stone; Craig Reeder; Kenton Wride; John Patin; Michele Schmidt; Jerome Zeldis; Robert Knight
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

4.  International scoring system for evaluating prognosis in myelodysplastic syndromes.

Authors:  P Greenberg; C Cox; M M LeBeau; P Fenaux; P Morel; G Sanz; M Sanz; T Vallespi; T Hamblin; D Oscier; K Ohyashiki; K Toyama; C Aul; G Mufti; J Bennett
Journal:  Blood       Date:  1997-03-15       Impact factor: 22.113

5.  Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program.

Authors:  Pellegrino Musto; Luca Maurillo; Alessandra Spagnoli; Antonella Gozzini; Flavia Rivellini; Monia Lunghi; Oreste Villani; Maria Antonietta Aloe-Spiriti; Adriano Venditti; Valeria Santini
Journal:  Cancer       Date:  2010-03-15       Impact factor: 6.860

6.  Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure.

Authors:  Thomas Prébet; Steven D Gore; Benjamin Esterni; Claude Gardin; Raphael Itzykson; Sylvain Thepot; François Dreyfus; Odile Beyne Rauzy; Christian Recher; Lionel Adès; Bruno Quesnel; C L Beach; Pierre Fenaux; Norbert Vey
Journal:  J Clin Oncol       Date:  2011-07-25       Impact factor: 44.544

Review 7.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Authors:  James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield
Journal:  Blood       Date:  2009-04-08       Impact factor: 22.113

8.  Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

Authors:  Azra Raza; James A Reeves; Eric J Feldman; Gordon W Dewald; John M Bennett; H Joachim Deeg; Luke Dreisbach; Charles A Schiffer; Richard M Stone; Peter L Greenberg; Peter T Curtin; Virginia M Klimek; Jamile M Shammo; Deborah Thomas; Robert D Knight; Michele Schmidt; Kenton Wride; Jerome B Zeldis; Alan F List
Journal:  Blood       Date:  2007-09-24       Impact factor: 22.113

9.  Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience.

Authors:  Sophie Park; Sophie Grabar; Charikleia Kelaidi; Odile Beyne-Rauzy; Françoise Picard; Valérie Bardet; Valérie Coiteux; Geneviève Leroux; Pascale Lepelley; Marie-Thérèse Daniel; Stéphane Cheze; Béatrice Mahé; Augustin Ferrant; Christophe Ravoet; Martine Escoffre-Barbe; Lionel Adès; Norbert Vey; Lina Aljassem; Aspasia Stamatoullas; Lionel Mannone; Hervé Dombret; Keith Bourgeois; Peter Greenberg; Pierre Fenaux; François Dreyfus
Journal:  Blood       Date:  2007-10-16       Impact factor: 22.113

10.  Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.

Authors:  Roger M Lyons; Thomas M Cosgriff; Sanjiv S Modi; Robert H Gersh; John D Hainsworth; Allen L Cohn; Heidi J McIntyre; Indra J Fernando; Jay T Backstrom; C L Beach
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544
View more
  11 in total

1.  Mutation in TET2 or TP53 predicts poor survival in patients with myelodysplastic syndrome receiving hypomethylating treatment or stem cell transplantation.

Authors:  M Kim; S-A Yahng; A Kwon; J Park; Y-W Jeon; J-H Yoon; S-H Shin; S-E Lee; B-S Cho; K-S Eom; S Lee; C-K Min; H-J Kim; S-G Cho; D-W Kim; J-W Lee; W-S Min; S-H Lee; Y-J Kim
Journal:  Bone Marrow Transplant       Date:  2015-05-11       Impact factor: 5.483

Review 2.  Myelodysplastic Syndromes: Updates and Nuances.

Authors:  Kim-Hien T Dao
Journal:  Med Clin North Am       Date:  2017-03       Impact factor: 5.456

3.  Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts.

Authors:  Pragya Srivastava; Benjamin E Paluch; Junko Matsuzaki; Smitha R James; Golda Collamat-Lai; Julia Karbach; Michael J Nemeth; Pietro Taverna; Adam R Karpf; Elizabeth A Griffiths
Journal:  Leuk Res       Date:  2014-09-10       Impact factor: 3.156

4.  Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms.

Authors:  Jonathan Benjamin; Saurabh Chhabra; Holbrook E Kohrt; Philip Lavori; Ginna G Laport; Sally Arai; Laura Johnston; David B Miklos; Judith A Shizuru; Wen-Kai Weng; Robert S Negrin; Robert Lowsky
Journal:  Biol Blood Marrow Transplant       Date:  2014-03-07       Impact factor: 5.742

Review 5.  Beyond hypomethylating agents failure in patients with myelodysplastic syndromes.

Authors:  Amer M Zeidan; Mohamed A Kharfan-Dabaja; Rami S Komrokji
Journal:  Curr Opin Hematol       Date:  2014-03       Impact factor: 3.284

6.  Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium.

Authors:  Elias J Jabbour; Guillermo Garcia-Manero; Paolo Strati; Asmita Mishra; Najla H Al Ali; Eric Padron; Jeffrey Lancet; Tapan Kadia; Naval Daver; Susan O'Brien; David P Steensma; Mikkael A Sekeres; Steven D Gore; Amy Dezern; Gail J Roboz; Alan F List; Hagop M Kantarjian; Rami S Komrokji
Journal:  Cancer       Date:  2014-11-19       Impact factor: 6.860

7.  Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system.

Authors:  Thomas Prebet; Pierre Fenaux; Norbert Vey
Journal:  Haematologica       Date:  2016-10       Impact factor: 9.941

8.  A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes.

Authors:  Guillermo Garcia-Manero; Hanna J Khoury; Elias Jabbour; Jeffrey Lancet; Shannon L Winski; LouAnn Cable; Selena Rush; Lara Maloney; Grant Hogeland; Mieke Ptaszynski; Monica Cabrero Calvo; Zach Bohannan; Alan List; Hagop Kantarjian; Rami Komrokji
Journal:  Clin Cancer Res       Date:  2014-12-05       Impact factor: 12.531

9.  Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial.

Authors:  M Tobiasson; I Dybedahl; M S Holm; M Karimi; L Brandefors; H Garelius; M Grövdal; I Högh-Dufva; K Grønbæk; M Jansson; C Marcher; L Nilsson; A O Kittang; A Porwit; L Saft; L Möllgård; E Hellström-Lindberg
Journal:  Blood Cancer J       Date:  2014-03-07       Impact factor: 11.037

10.  Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome : a retrospective study from The Korean Society of Hematology AML/MDS Working Party.

Authors:  Da Jung Kim; Ho Sup Lee; Joon-Ho Moon; Sang Kyun Sohn; Hyeoung Joon Kim; June-Won Cheong; Deog-Yeon Jo; Hawk Kim; Hyewon Lee; Soo-Mee Bang; Won Sik Lee; Yong Park; Mark Hong Lee; Jae Hoon Lee; Sung Hwa Bae; Min Kyoung Kim
Journal:  Oncotarget       Date:  2017-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.